Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2018

Study Completion Date

April 30, 2019

Conditions
Neuroendocrine TumorsHepatic MetastasesMetastases
Interventions
DRUG

Everolimus

10 mg per day of everolimus during 24 months or until progression disease

DEVICE

embolization

2 sessions embolization with spheric particles

DRUG

Doxorubicin

2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine

Trial Locations (18)

Unknown

CHU - Hôtel Dieu, Angers

Hôpital Avicenne, Bobigny

Hôpital Saint André, Bordeaux

Hôpital Côte de Nacre, Caen

CHU - Estaing, Clermont-Ferrand

Hôpital Beaujon, Clichy

Centre GF Leclerc, Dijon

CHU - Hôpital François Mitterand, Dijon

Hôpital Edouard Herriot, Lyon

CHU La Timone, Marseille

CHR, Orléans

CHU Cochin, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Robert Debré, Reims

CHU, Rouen

Hôpital Rangueil, Toulouse

Hôpital Trousseau, Tours

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER

NCT01678664 - Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | Biotech Hunter | Biotech Hunter